Clinical trials: Embryonal Neoplasm
Retinoblastoma
Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma
The primary objective of this protocol is to evaluate the response rate of bilateral disease participants who have at least one eye with advanced intra-ocular retinoblastoma (stratum B) using upfront therapy with chemotherapy…
- Trial name
- NCT01783535
- Testing
- vincristine, topotecan, filgrastim
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- St. Jude Children's Research Hospital
Medulloblastoma, Brain Tumors
High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood
The purpose of this study is to evaluate the efficacy of the combination of surgery, conventional chemotherapy, sequential high-dose chemotherapy with peripheral blood stem cell transplantation and reduced dose radiation therapy…
- Conditions
- Medulloblastoma, Brain Tumors, Neuroectodermal Tumors, Primitive
- Trial name
- NCT00180791
- Testing
- Etoposide, carboplatin, melphalan, cisplatin, thiotepa
- Where
- France
- Volunteers
- 71 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
This is a phase I, open label, plus expansion clinical trial evaluating the safety and tolerability of rHSC-DIPGVax in combination with BALSTILIMAB and ZALIFRELIMAB.
- Trial name
- NCT04943848
- Testing
- rHSC-DIPGVax, Balstilimab, Zalifrelimab
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Type 2
Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
Background: Medullary thyroid carcinoma (MTC) is a rare malignancy, occurring either as a sporadic disease (75% of cases), or in a hereditary pattern as multiple endocrine neoplasia (MEN) type 2 (MEN2A or MEN2B) or familial…
- Trial name
- NCT01424878
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute (NCI)
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
Craniopharyngioma, Apoplexy
Craniopharyngioma With Tumoral Hemorrhage
Clinical data of 185 consecutive patients receiving resective operation with a pathological diagnosis of craniopharyngioma in our hospital between January 2013 and February 2021 were collected.
- Trial name
- NCT04937335
- Testing
- intratumoral hemorrhage
- Volunteers
- 185 people
- Sponsor
- Tongji Hospital
Germ Cell Ovarian Cancer, Germ Cell Tumor
SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours
The goal of this observational case-control study is to learn about the circulating and tissue microRNA expression, imaging and radiomic profiles of malignant ovarian germ cell tumours (MOGCT) compared to patients with a benign…
- Conditions
- Germ Cell Ovarian Cancer, Germ Cell Tumor, Germ Cell Cancer, Germ Cell Neoplasia
- Trial name
- SUMMER (NCT06329323)
- Testing
- Blood test, Pathology specimen miRNA expression
- Volunteers
- 24 people
- Sponsor
- Imperial College London
Brain and Central Nervous System Tumors, Lymphoma
Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma
- Trial name
- NCT00053118
- Testing
- filgrastim, carboplatin, etoposide
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Roswell Park Cancer Institute
Malignant Melanoma
A Study of Vemurafenib in Participants With Metastatic Melanoma
This multi-center study evaluates the safety and efficacy of vemurafenib in participants with BRAF V600 mutation-positive, surgically incurable, and unresectable Stage IIIC or IV (American Joint Committee on Cancer [AJCC])…
- Trial name
- NCT01307397
- Testing
- Vemurafenib
- Where
- 280 sites in Albania, Argentina and 42 more
- Volunteers
- 3,219 people
- Sponsor
- Hoffmann-La Roche
Brain Tumor, Central Nervous System Tumors
Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it is no longer present by…
- Conditions
- Brain Tumor, Central Nervous System Tumors, Childhood Germ Cell Tumor
- Trial name
- NCT00047320
- Testing
- carboplatin, etoposide, ifosfamide
- Where
- 106 sites in United States, Australia and 3 more
- Volunteers
- 104 people
- Sponsor
- Children's Oncology Group
Congenital Hyperinsulinism, Neuroblastoma
18F-DOPA II - PET Imaging Optimization
A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients (less than 18 years old) with congenital hyperinsulinism. 2.
- Conditions
- Congenital Hyperinsulinism, Neuroblastoma, Parkinson Disease, Lewy Body Disease
- Trial name
- NCT04706910
- Testing
- 18F-DOPA, Furosemide Injection
- Where
- Canada
- Volunteers
- 800 people
- Sponsor
- University of Alberta
Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3
Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
This phase 1b trial studies the side effects and best dose of telaglenastat in combination with radiation therapy and temozolomide in treating patients with IDH-mutated diffuse or anaplastic astrocytoma.
- Trial name
- NCT03528642
- Testing
- Questionnaire Administration, Radiation Therapy, Telaglenastat Hydrochloride
- Where
- 25 sites in United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumor Recurrent
Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Ependymoma
The goal of this clinical research study is to establish the safety of direct administration of 5-Azacytidine into the fourth ventricle of the brain or resection cavity in patients with recurrent posterior fossa ependymoma.
- Trial name
- 5-AZA (NCT02940483)
- Testing
- 5-Azacytidine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- The University of Texas Health Science Center, Houston
Neuroblastoma, Sarcoma
Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody A1G4 with BCG may kill more tumor cells.
- Trial name
- NCT00003023
- Testing
- BCG vaccine, monoclonal antibody A1G4 anti-idiotype vaccine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor
Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
This phase I trial investigates the side effects and effectiveness of chemotherapy followed by a donor (allogeneic) stem cell transplant when given to patients with high grade brain cancer.
- Conditions
- Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Germ Cell Tumor, Choroid Plexus Carcinoma
- Trial name
- NCT04521946
- Testing
- Etoposide, Fludarabine Phosphate, Hematopoietic Cell Transplantation
- Volunteers
- healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Lymphoma
Adolescent and Young Adult Cancer Patients: Cognitive Toxicity on Survivorship (ACTS)
This study aims to evaluate the prevalence, biological mechanism and survivorship impact of cognitive toxicity among adolescent and young adult (AYA) patients diagnosed with curable cancers.
- Conditions
- Breast Cancer, Lymphoma, Germ Cell Tumor, Cognitive Impairment
- Trial name
- NCT03476070
- Where
- 3 sites in Singapore
- Volunteers
- 236 people, healthy volunteers welcome
- Sponsor
- National University of Singapore
Glioblastoma of Cerebellum
DLL3 CAR-T Therapy Targeting Brain Tumors
The purpose of this study is to assess the feasibility, safety and efficacy of Delta-like ligand 3 (DLL3)-specific CAR-T cell therapy in patients with DLL3 positive brain tumors including glioblastomas and diffused intrinsic…
- Trial name
- NCT07180927
- Testing
- 4SCAR DLL3 T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Neuroendocrine Tumors
Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
This is a prospective single arm, multicenter study will evaluate the efficacy and safety of Lutetium-177 Octreotate in patients with neuroendocrine tumors who has positive Somatostatin receptor identified by 68Ga-DOTATATE.
- Trial name
- NCT02743741
- Testing
- Lutetium-177 Octreotate
- Where
- 4 sites in Canada
- Volunteers
- 195 people
- Sponsor
- University Health Network, Toronto
Pheochromocytoma and Paraganglioma (PPGL), Pheochromocytoma Malignant
An Experimental Study of Belzutifan Impact on Catecholamine Metabolism
To investigate the impact of a medication called Belzutifan on the production and subsequent metabolism of adrenaline and noradrenaline collectively termed 'catecholamines'.
- Conditions
- Pheochromocytoma and Paraganglioma (PPGL), Pheochromocytoma Malignant, Pheochromocytoma, Metastatic, Pheochromocytoma/Paraganglioma
- Trial name
- NCT07680205
- Testing
- Belzutifan
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Medulloblastoma
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.
- Trial name
- NCT04696029
- Testing
- Difluoromethylornithine
- Where
- 26 sites in United States, Canada
- Volunteers
- 118 people
- Sponsor
- Giselle Sholler